The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function
Silvia Sookoian, Carlos J. Pirola – 2 December 2017
Gentle palpating liver sinusoidal endothelial cells reveals the dynamic behavior and formation of fenestrae: A new window for biomedical research
Filip Braet, Eddie Wisse – 2 December 2017
Peacekeepers are cross‐dressed in the liver land
Yuan Zhai, Jerzy W. Kupiec‐Weglinski – 1 December 2017
Checkpoint modulation in chronic hepatitis B: From hypothesis to approval
Georgios Germanidis, Prodromos Hytiroglou, Themistoklis Vassiliadis, Matthaios Speletas – 1 December 2017
Bringing the cell nucleus in the focus of NAFLD
Kurt Zatloukal – 1 December 2017
Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine
Khaled Alnuaimi, Julie Lavolé, Caroline Lascoux‐Combes, Anne‐Marie Roque Afonso, Philippe Sogni, Stanislas Pol, Vincent Mallet – 1 December 2017
Scratching the surface of cholestatic itch treatments
Christopher L. Bowlus – 1 December 2017
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience
Riad Salem, Ahmed Gabr, Ahsun Riaz, Ronald Mora, Rehan Ali, Michael Abecassis, Ryan Hickey, Laura Kulik, Daniel Ganger, Steven Flamm, Rohi Atassi, Bassel Atassi, Kent Sato, Al B. Benson, Mary F. Mulcahy, Nadine Abouchaleh, Ali Al Asadi, Kush Desai, Bartley Thornburg, Michael Vouche, Ali Habib, Juan Caicedo, Frank H. Miller, Vahid Yaghmai, Joseph R. Kallini, Samdeep Mouli, Robert J. Lewandowski – 1 December 2017 – Yttrium‐90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for hepatocellular carcinoma (HCC).
Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct‐acting antiviral regimens matter?
Fanpu Ji, Yee Hui Yeo, Mike Tzuhen Wei, Bin Wei, Shuangsuo Dang, Zongfang Li, Mindie H. Nguyen – 1 December 2017
Impact of hepatitis C virus polymorphisms on direct‐acting antiviral treatment efficacy: Regulatory analyses and perspectives
Patrick R. Harrington, Takashi E. Komatsu, Damon J. Deming, Eric F. Donaldson, Julian J. O'Rear, Lisa K. Naeger – 1 December 2017 – Several highly effective, interferon‐free, direct‐acting antiviral (DAA)‐based regimens are available for the treatment of chronic hepatitis C virus (HCV) infection. Despite impressive efficacy overall, a small proportion of patients in registrational trials experienced treatment failure, which in some cases was associated with the detection of HCV resistance‐associated substitutions (RASs) at baseline.